Get started
Author

Ф. И. Нагимова

Observed names: F I Nagimova, F Nagimova, F. I. Nagimova, F. Nagimova, F.I. Nagimova, Firaya I. Nagimova, Firaya Nagimova, Нагимова Ф.И., Ф И Нагимова
Observed institutions: University of Nevada, Reno, Kazan State Medical University, Kazan Federal University, Centre for Prevention and Control of AIDS and Infectious Diseases, Pitié-Salpêtrière Hospital, Republican Center for the Prevention and Control of AIDS and Infectious Diseases
ORCID: 0000-0002-5703-6712
Observed ORCID: 0000-0002-5703-6712
OpenAlex ID: A5056289551
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials
2018 · Pedro Cahn, Juan Sierra Madero, et al. · The Lancet · 399
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
2020 · Edgar T Overton, Gary Richmond, et al. · The Lancet · 397
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial
2018 · Jean-Michel Molina, Kathleen Squires, et al. · The Lancet HIV · 153
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial
2019 · Jean-Michel Molina, Kathleen Squires, et al. · The Lancet HIV · 100
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials
2023 · Chloe Orkin, Jean-Michel Molina, et al. · The Lancet HIV · 37
Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial
2017 · Pedro Cahn, Richard Kaplan, et al. · The Lancet HIV · 35
PDF
Efficacy and safety of novel russian non-nucleoside reverse transcriptase inhibitor elsulfavirine in combination with 2 nucleoside/nucleotide reverse transcriptase inhibitors in first-line HIV treatment – 96-week study
2018 · A. V. Kravchenko, E. A. Orlova-Morozova, et al. · Journal Infectology · 11
PDF
Dynamics of Manifestations of the Epidemic Process of Hiv Infection in Relation With the Epidemiological Situation for Addiction (in the Republic of Tatarstan)
2019 · G. R. Khasanova, C. T. Agliullina, et al. · HIV Infection and Immunosuppressive Disorders · 5
PDF
Concomitant Diseases and Risk Factors for Their Development in Patients With Hiv Infection Older Than 40 Years
2017 · D. A. Gusev, S. A. Buzunova, et al. · Journal Infectology · 5
PDF
Analysis of HIV-infection incidence in women in the Tatarstan Republic
2016 · S.T. Agliullina, G.R. Khasanova, et al. · Kazan medical journal · 4
Peculiarities of HIV-positive patients coinfection with hepatitis C virus
2014 · D V Pavlov, D Kh Shakirova, et al. · Kazan medical journal · 4
PDF
Changes of intestinal microbiota in patients with HIV
2013 · G R Khasanova, V A Anokhin, et al. · Kazan medical journal · 3
PDF
Epidemiological assessment of factors associated with late diagnosis of HIV infection
2022 · Gulshat R. Khasanova, Saida T. Agliullina, et al. · Kazan medical journal · 2
Dynamics of Epidemiological Manifestations of HIV Infection in the Gender Aspect (on the Example of the Republic of Tatarstan)
2020 · G. R. Khasanova, S. T. Agliullina, et al. · Epidemiology and Vaccinal Prevention · 2
PDF
Efficacy and safety of novel russian non-nucleoside reverse transcriptase inhibitor elsulfavirine in combination with tenofovir/emtricitabine – multicenter comparative trial vs efavirenz in naїve HIV patients
2017 · A.V. Kravchenko, E.A. Orlova-Morozova, et al. · Infekcionnye bolezni · 2
The HIV integrase inhibitor raltegravir as part of antiretroviral therapy schemes in patients with HIV infection and hepatitis C
2015 · A.V. Kravchenko, V.Ya. Aksenova, et al. · Infekcionnye bolezni · 2
Factors associated with late HIV diagnosis
2022 · G. R. Khasanova, S. T. Agliullina, et al. · Fundamental and Clinical Medicine · 1
PDF
The Results of the Efficacy and Safety of the New Russian Drug 6нр in the Antiretroviral Therapy Regimens of Hiv-infected Patients
2019 · A. V. Kravchenko, N. V. Sizova, et al. · Journal Infectology · 1
PDF
Significance of Polymorphism in 2’,5’-Oligoadenylate Synthetase Genes in HIV Infection
2016 · L.B. Bakhteeva, S.F. Khaibullina, et al. · Современные технологии в медицине · 1
PDF
Cepeginterferon alfa-2b in combination with ribavirin for treatment of chronic hepatitis C in patients co-infected with HIV-1 (final results of a multicenter randomized study)
2016 · F. Nagimova, V. Rassokhin, et al. · Infekcionnye bolezni · 1
1617Safety, Tolerability, and Antiretroviral Activity of Raltegravir in HIV-1 Infected Russian Children and Adolescents – a 24 Week Study
2014 · Hedy Teppler, Andrey Shuldyakov, et al. · Open Forum Infectious Diseases · 1
PDF
Multicenter epidemiological study to describe prevalence of advanced stage disease among newly diagnosed HIV‐infected patients in the Russian Federation
2012 · A Pronin, E Orlova‐Morozova, et al. · Journal of the International AIDS Society · 1
PDF
Disseminated Kaposi’s sarcoma in patient with human immunodeficiency virus infection
2023 · Liliya B. Bahteeva, Maya B. Sharaeva, et al. · Epidemiology and Infectious Diseases
PDF
Multifactoriality of HIV morbidity dynamics among females in the Republic of Tatarstan
2017 · S T Agliullina, G R Khasanova, et al. · Kazan medical journal
PDF
P1175 CEPEGINTERFERON-ALFA-2b IN COMBINATION WITH RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C
2014 · O. Znoyko, E. Klimova, et al. · Journal of Hepatology
Works count: 36
Citation count: 1,167
H-index: 7
I10-index: 7
Year
Topic
Type